1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Emma Walmsley
|
|||
b)
|
Position/status
|
Chief
Executive Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.7047
|
7 (partnership shares)
|
|
||
|
£15.7047
|
7 (matching shares)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated
volume
Price
|
14 Ordinary Shares
£15.7047
|
||||
e)
|
Date
of the transaction
|
2024-01-10
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Julie Brown
|
|||
b)
|
Position/status
|
Chief
Financial Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
c)
|
|
|
Price(s)
|
Volume(s)
|
|
|
£15.7047
|
8 (partnership shares)
|
|
||
|
£15.7047
|
8 (matching shares)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated
volume
Price
|
16 Ordinary Shares
£15.7047
|
||||
e)
|
Date
of the transaction
|
2024-01-10
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
James Ford
|
|||
b)
|
Position/status
|
SVP and
Group General Counsel, Legal and Compliance
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.7047
|
8 (partnership shares)
|
|
||
|
£15.7047
|
8 (matching shares)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated
volume
Price
|
16 Ordinary Shares
£15.7047
|
||||
e)
|
Date
of the transaction
|
2024-01-10
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Sally Jackson
|
|||
b)
|
Position/status
|
SVP,
Global Communications and CEO Office
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.7047
|
8 (partnership shares)
|
|
||
|
£15.7047
|
8 (matching shares)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated
volume
Price
|
16 Ordinary Shares
£15.7047
|
||||
e)
|
Date
of the transaction
|
2024-01-10
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
David Redfern
|
|||
b)
|
Position/status
|
President
Corporate Development
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.7047
|
8 (partnership shares)
|
|
||
|
£15.7047
|
8 (matching shares)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated
volume
Price
|
16 Ordinary Shares
£15.7047
|
||||
e)
|
Date
of the transaction
|
2024-01-10
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Regis Simard
|
|||
b)
|
Position/status
|
President,
Global Supply Chain
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.7047
|
8 (partnership shares)
|
|
||
|
£15.7047
|
8 (matching shares)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated
volume
Price
|
16 Ordinary Shares
£15.7047
|
||||
e)
|
Date
of the transaction
|
2024-01-10
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Phil Thomson
|
|||
b)
|
Position/status
|
President,
Global Affairs
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.7047
|
8 (partnership shares)
|
|
||
|
£15.7047
|
8 (matching shares)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated
volume
Price
|
16 Ordinary Shares
£15.7047
|
||||
e)
|
Date
of the transaction
|
2024-01-10
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Deborah Waterhouse
|
|||
b)
|
Position/status
|
CEO,
ViiV Healthcare and President, Global Health, GSK
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.7047
|
8 (partnership shares)
|
|
||
|
£15.7047
|
8 (matching shares)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated
volume
Price
|
16 Ordinary Shares
£15.7047
|
||||
e)
|
Date
of the transaction
|
2024-01-10
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Victoria Whyte
|
|||
b)
|
Position/status
|
Company
Secretary
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.7047
|
8 (partnership shares)
|
|
||
|
£15.7047
|
8 (matching shares)
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
|
|||
Aggregated
volume
Price
|
16 Ordinary Shares
£15.7047
|
||||
e)
|
Date
of the transaction
|
2024-01-10
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Emma Walmsley
|
|||
b)
|
Position/status
|
Chief
Executive Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024 on shares held
through the Company's Share Reward Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.6519
|
22
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-01-11
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Diana Conrad
|
|||
b)
|
Position/status
|
Chief People Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024 on shares held
through the Company's Share Reward Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.6519
|
5
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-01-11
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
James Ford
|
|||
b)
|
Position/status
|
SVP and Group General Counsel, Legal and Compliance
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024 on shares held
through the Company's Share Reward Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.6519
|
6
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-01-11
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Sally Jackson
|
|||
b)
|
Position/status
|
SVP,
Global Communications and CEO Office
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024 on shares held
through the Company's Share Reward Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.6519
|
51
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-01-11
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Luke Miels
|
|||
b)
|
Position/status
|
Chief
Commercial Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024 on shares held
through the Company's Share Reward Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.6519
|
3
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-01-11
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
David Redfern
|
|||
b)
|
Position/status
|
President
Corporate Development
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024 on shares held
through the Company's Share Reward Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.6519
|
62
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-01-11
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Regis Simard
|
|||
b)
|
Position/status
|
President,
Global Supply Chain
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024 on shares held
through the Company's Share Reward Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.6519
|
22
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-01-11
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Phil Thomson
|
|||
b)
|
Position/status
|
President,
Global Affairs
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024 on shares held
through the Company's Share Reward Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.6519
|
38
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-01-11
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Deborah Waterhouse
|
|||
b)
|
Position/status
|
CEO,
ViiV Healthcare
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024 on shares held
through the Company's Share Reward Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.6519
|
51
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-01-11
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Victoria Whyte
|
|||
b)
|
Position/status
|
Company
Secretary
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024 on shares held
through the Company's Share Reward Plan
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.6519
|
46
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-01-11
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Dylan Jackson
|
|||
b)
|
Position/status
|
PCA of Ms S Jackson (SVP, Global Communications and CEO
Office)
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.7208
|
21
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-01-11
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Iain Whyte
|
|||
b)
|
Position/status
|
PCA of Ms V Whyte (Company Secretary)
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 January 2024.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.7208
|
903
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2024-01-11
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||||
a)
|
Name
|
David
Redfern
|
|||
b)
|
Position/status
|
Chief
Strategy Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description of the
financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 11 January 2024, on Ordinary Shares held
within an ISA
|
|||
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.6989
|
17
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date of
the transaction
|
2024-01-12
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||||
a)
|
Name
|
Victoria
Whyte
|
|||
b)
|
Position/status
|
Company
Secretary
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description of the
financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 11 January 2024, on Ordinary Shares held
within an ISA
|
|||
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.6989
|
14
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date of
the transaction
|
2024-01-12
|
|||
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||||
a)
|
Name
|
Elizabeth
McKee Anderson
|
|||
b)
|
Position/status
|
Independent
Non-Executive Director
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description of the
financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 11 January 2024
|
|||
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$40.1022
|
8
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date of
the transaction
|
2024-01-12
|
|||
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||||
a)
|
Name
|
Charles
Bancroft
|
|||
b)
|
Position/status
|
Independent
Non-Executive Director
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description of the
financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 11 January 2024
|
|||
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$40.1022
|
46
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date of
the transaction
|
2024-01-12
|
|||
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||||
a)
|
Name
|
Dr Hal
Barron
|
|||
b)
|
Position/status
|
Non-Executive
Director
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description of the
financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 11 January 2024
|
|||
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$40.1022
|
11
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date of
the transaction
|
2024-01-12
|
|||
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||||
a)
|
Name
|
Dr Anne
Beal
|
|||
b)
|
Position/status
|
Independent
Non-Executive Director
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description of the
financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 11 January 2024
|
|||
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$40.1022
|
6
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date of
the transaction
|
2024-01-12
|
|||
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||||
a)
|
Name
|
Dr
Harry Dietz
|
|||
b)
|
Position/status
|
Independent
Non-Executive Director
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description of the
financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 11 January 2024
|
|||
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$40.1022
|
6
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date of
the transaction
|
2024-01-12
|
|||
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||||
a)
|
Name
|
Dr
Jesse Goodman
|
|||
b)
|
Position/status
|
Independent
Non-Executive Director
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description of the
financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 11 January 2024
|
|||
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$40.1022
|
6
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date of
the transaction
|
2024-01-12
|
|||
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
||||
a)
|
Name
|
Dr
Vishal Sikka
|
|||
b)
|
Position/status
|
Independent
Non-Executive Director
|
|||
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GSK
plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description of the
financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 11 January 2024
|
|||
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$40.1022
|
32
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date of
the transaction
|
2024-01-12
|
|||
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|
GSK plc
|
|
(Registrant)
|
|
|
Date: January
16, 2024
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|